Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Annual General Meeting: Fresenius on course for continued growth, 26th straight increase in dividend approved

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2019 | 09:33am EDT

Fresenius remains on course for growth despite some recent challenges, Stephan Sturm, CEO of Fresenius, told the Annual General Meeting in Frankfurt today. '2018 was not an easy year, and yet it was a successful one,' he said in a speech to shareholders. 'Fresenius is in very good shape. All indications point to continued, profitable growth.'

The basis for this will be increased investments in the current business year, Sturm said. He confirmed the global healthcare group's ambitious targets1 for 2020 to 2023 of organic sales growth averaging 4 to 7 percent annually and an average increase in net income2 of 5 to 9 percent.

'What we do is more important than ever,' Sturm said. 'The healthcare market is growing. People are living longer, and around the world the demand for high-quality medicine is rising. Needs and expectations are also changing: It is no longer about preserving lives, but about raising quality of life for people well into old age. It is also about keeping quality healthcare affordable. These are big challenges! But challenges that we are superbly positioned to meet.'

Shareholders approved with a majority of 90.96 percent the proposal of the General Partner and the Supervisory Board to increase the dividend for the 26th consecutive time. It was raised by 7 percent, to €0.80 per share.

Shareholder majorities of 98.49 percent and 87.53 percent, respectively, approved the actions of the Management and Supervisory Boards in 2018.

At the Annual General Meeting, 72.46 percent of the subscribed capital was represented.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Disclaimer

Fresenius SE & Co. KGaA published this content on 17 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 17 May 2019 13:32:08 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS SE & CO. KGAA
09/16FRESENIUS : 2020 DRG inflator for German hospitals set at 3.66%
PU
09/15Fresenius drops possible sale of blood transfusion unit - spokesman
RE
09/13FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
09/11FRESENIUS : Helios launches digital portal for patients
PU
09/09FRESENIUS : Medical Care's publishes annual medical report
PU
09/06FRESENIUS : Medical Care builds new laboratory in Mississippi
PU
09/05Fresenius Medical Care to Invest in Its Stem-Cell Subsidiary Unicyte
DJ
09/05FRESENIUS : Medical Care invests EUR 60 million in Unicyte
PU
09/03Fresenius Helios Acquires Two Hospitals in Colombia
DJ
08/30FRESENIUS : Kabi launches IV Drug in the U.S.
PU
More news
Financials (EUR)
Sales 2019 35 385 M
EBIT 2019 4 647 M
Net income 2019 1 839 M
Debt 2019 20 938 M
Yield 2019 1,76%
P/E ratio 2019 13,7x
P/E ratio 2020 12,5x
EV / Sales2019 1,31x
EV / Sales2020 1,16x
Capitalization 25 246 M
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 56,68  €
Last Close Price 45,27  €
Spread / Highest target 65,2%
Spread / Average Target 25,2%
Spread / Lowest Target -28,3%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors